IDEAYA Biosciences, Inc.
IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update
Data presented at ESMO 2026 collectively supports the potential of darovasertib to become a foundational new therapy across the treatment journey of…